Intuitive Surgical
ISRG
$450.62
-0.95%
Intuitive Surgical Inc. is a global leader in robotic-assisted minimally invasive surgery, primarily through its da Vinci surgical systems, which are complemented by a high-margin recurring revenue stream from instruments, accessories, and services. The company is the dominant, entrenched market leader in the surgical robotics space, with a massive installed base and a powerful competitive moat built on surgeon training, clinical data, and a sticky ecosystem. The current investor narrative is dominated by a tension between the company's robust underlying business growth and significant near-term headwinds, including a recent FDA safety flag on a stapler product and concerns over its sky-high valuation, which has led to a sharp stock price correction from recent highs.…
ISRG
Intuitive Surgical
$450.62
Related headlines
ISRG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $585.81 and implied upside of +30.0% versus the current price.
Average Target
$585.81
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$361 - $586
Analyst target range
Analyst coverage is moderate with 11 firms providing estimates, indicating solid institutional interest. The consensus sentiment appears mixed but leans bullish, as evidenced by recent actions from Citigroup (upgrade to Buy in March) and Freedom Capital Markets (upgrade to Buy in January), though other firms have maintained Neutral or equivalent ratings. The average revenue estimate for the coming period is $18.89 billion, with a wide range from $18.07B to $19.96B, reflecting some uncertainty around the growth trajectory. The target price range is not explicitly provided in the data, but the wide spread between high and low revenue estimates ($18.07B to $19.96B) signals meaningful divergence in analyst views on the company's near-term prospects. The high-end estimates likely assume successful navigation of regulatory headlines, continued system placement growth, and strong pull-through of high-margin instruments. The low-end estimates may factor in potential headwinds from the FDA safety concern, competitive pressures, or a macroeconomic slowdown impacting hospital capital expenditures. The recent pattern of institutional ratings shows a mix of reiterations and selective upgrades, suggesting analysts are closely monitoring the situation but are not yet in a broad downgrade cycle.
Bulls vs Bears: ISRG Investment Factors
The investment debate for ISRG centers on the tension between its exceptional, high-margin fundamental business and its extreme valuation facing near-term headwinds. Currently, the bear case holds stronger evidence due to the stock's severe technical breakdown and the concrete regulatory overhang, which directly challenge the premium multiple. The single most important factor is the resolution of the FDA safety concern; a swift and favorable resolution could restore confidence and validate the growth narrative, while prolonged issues or market share loss would likely trigger further valuation compression. The robust underlying growth (18.76% YoY) and profitability provide a solid foundation, but the stock remains a 'show me' story where execution must now catch up to the price.
Bullish
- Exceptional Profitability & Margins: The company maintains elite profitability with a Q4 2025 net margin of 27.73% and a gross margin of 66.44%, far exceeding typical medtech peers. This financial strength, coupled with a fortress balance sheet (Debt/Equity of 0.017), provides immense flexibility to navigate headwinds and invest in growth.
- Robust Underlying Revenue Growth: Q4 2025 revenue grew 18.76% year-over-year to $2.87 billion, demonstrating strong underlying business momentum. The revenue model is highly recurring, with Instruments & Accessories ($1.66B) representing the largest segment, creating a sticky ecosystem and predictable cash flow.
- Dominant Market Position & Moat: With over 10,000 da Vinci systems installed globally, Intuitive possesses a massive installed base, surgeon training lock-in, and a vast clinical data library. This entrenched leadership creates a powerful competitive moat that is difficult for new entrants to overcome.
- Strong Cash Generation & Liquidity: The company generated $2.49 billion in trailing twelve-month free cash flow and holds a current ratio of 4.87. This robust cash generation funds innovation and shareholder returns without reliance on debt, providing a significant buffer during market uncertainty.
Bearish
- Extreme Valuation Premium: ISRG trades at a trailing P/E of 70.78x and a Price/Sales of 20.1x, representing a substantial premium to the broader medtech sector. This sky-high valuation leaves the stock vulnerable to multiple compression if growth expectations falter or market sentiment sours.
- Significant Regulatory & Product Headwind: A recent FDA safety flag on a stapler product represents a tangible near-term risk to the company's reputation and instrument revenue stream. This regulatory concern is a primary catalyst for the stock's 23% decline over the past three months and introduces execution uncertainty.
- Pronounced Technical Downtrend: The stock is down 23.13% over three months and trades at $450.62, just 75% of its 52-week high of $603.88. With a 1-month relative strength of -9.03 against the market, persistent selling pressure and a breakdown below the $428 support level could trigger further declines.
- High Volatility & Market Sensitivity: A beta of 1.679 indicates the stock is approximately 68% more volatile than the broader market. This high volatility has amplified the recent downside move and increases portfolio risk, making the stock unsuitable for risk-averse investors during periods of market stress.
ISRG Technical Analysis
The stock is in a pronounced downtrend, having declined 7.95% over the past year and a severe 23.13% over the last three months, significantly underperforming the S&P 500's 29.52% and -2.1% returns over the same periods, respectively. Currently trading at $450.62, the price sits at just 75% of its 52-week high of $603.88, indicating it is substantially off its peak and in a corrective phase, though it remains above the 52-week low of $427.84. Recent momentum is decisively negative, with the stock down 8.57% over the past month, which accelerates the longer-term downtrend and signals persistent selling pressure, further evidenced by a 1-month relative strength of -9.03 against the market. This divergence from the market's modest gains suggests company-specific concerns are driving the weakness, not broad market sentiment. Key technical support is at the 52-week low of $427.84, while resistance is at the recent high of $603.88. A breakdown below the $428 support level would signal a continuation of the bearish trend and potentially open the door to further declines, whereas a sustained move above the descending trendline would be needed to suggest a reversal. The stock's beta of 1.679 indicates it is approximately 68% more volatile than the broader market, which has amplified its downside move during this correction and is a critical factor for risk-aware investors considering position sizing.
Beta
1.68
1.68x market volatility
Max Drawdown
-24.1%
Largest decline past year
52-Week Range
$428-$604
Price range past year
Annual Return
-7.9%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | -8.6% | +2.6% |
| 3m | -23.1% | -2.3% |
| 6m | +4.9% | +2.6% |
| 1y | -7.9% | +27.3% |
| ytd | -19.8% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $2.87 billion representing a strong 18.76% year-over-year increase, and sequential growth from Q3's $2.51 billion demonstrates continued momentum. The revenue segment data shows Instruments and Accessories ($1.66B) as the largest and most recurring contributor, followed by Systems ($785.9M) and Services ($422M), indicating a healthy, high-margin recurring revenue model is firmly in place. This growth trajectory underscores the underlying strength of the business despite the stock's technical weakness. Profitability is exceptional, with Q4 2025 net income of $794.8 million and a net margin of 27.73%, supported by a gross margin of 66.44%. Margins have expanded year-over-year, as the Q4 2024 gross margin was 68.04% and net margin was 28.41%, showing some normalization but remaining at elite levels for the medtech industry. The company is solidly profitable with industry-leading margins, providing significant financial flexibility. The balance sheet is fortress-like, with a minimal debt-to-equity ratio of 0.017 and a strong current ratio of 4.87, indicating ample liquidity. The company generates substantial cash, with trailing twelve-month free cash flow of $2.49 billion, which easily funds its growth initiatives and share repurchases. A return on equity of 16.02% demonstrates efficient use of shareholder capital, cementing the view of a fundamentally healthy company navigating a valuation reset.
Quarterly Revenue
$2.9B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.66%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given the company's substantial net income, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 70.78x, while the forward P/E is significantly lower at 39.43x, indicating the market expects strong earnings growth to bring the valuation down to a more reasonable level over the next twelve months. The wide gap between trailing and forward multiples reflects high embedded growth expectations. Compared to sector averages, ISRG trades at a substantial premium. While specific industry average multiples are not provided in the data, its trailing P/E of 70.8x and Price/Sales of 20.1x are typically far above those of traditional medical device companies. This premium has historically been justified by its monopolistic market position, superior growth profile, and exceptional profitability, but the recent compression suggests the market is re-evaluating that premium. Historically, the stock's current trailing P/E of 70.8x is below its recent peak observed in the historical ratios data (e.g., 77.3x in Q3 2024) but remains well above levels seen in earlier years like 2021 (52.7x in Q2 2021). Trading near the middle-to-upper end of its own multi-year historical valuation range suggests the stock is no longer at peak optimism, but the valuation still implies high expectations that must be met through flawless execution, especially in light of recent regulatory concerns.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~84x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are currently low but center on valuation sustainability rather than solvency. The primary risk is that the company's high growth rate (18.76% YoY) and net margin (27.73%) must be maintained to justify its trailing P/E of 70.8x. Any deceleration in revenue growth or margin contraction—potentially from the FDA stapler issue impacting high-margin instrument sales—could trigger a severe de-rating. The company's minimal debt (D/E 0.017) and strong cash flow ($2.49B FCF) mitigate traditional financial risk, but the operational risk is concentrated in its ability to flawlessly execute within a regulated environment.
Market & Competitive Risks are elevated. The stock's premium valuation (P/S 20.1x) makes it acutely sensitive to sector rotations away from high-multiple growth stocks, especially in a higher interest rate environment. Its beta of 1.679 means it will experience amplified moves during broader market downturns. While its competitive moat is strong, the regulatory headline provides an opening for competitors and could slow adoption momentum if hospital purchasing committees become more cautious. The recent news of an FDA safety flag is a tangible example of this external risk materializing.
The Worst-Case Scenario involves the FDA stapler concern escalating into a broader product recall or usage restrictions, leading to a significant slowdown in system placements and instrument pull-through. Combined with a risk-off market environment compressing growth stock multiples, this could drive the stock to re-test and break its 52-week low of $427.84. A realistic downside from the current price of $450.62 could be a decline of 20-25%, targeting a range of $360-$400, which would align with a forward P/E in the low 30s—still a premium but reflecting materially reduced growth expectations. The stock's 24.09% max drawdown indicates such volatility is within its recent historical range.